News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
583,029 Results
Type
Article (39862)
Company Profile (84)
Press Release (543074)
Multimedia
Podcasts (110)
Webinars (20)
Section
Business (174877)
Career Advice (2187)
Deals (28789)
Drug Delivery (93)
Drug Development (62069)
Employer Resources (149)
FDA (14040)
Job Trends (12654)
News (286188)
Policy (27245)
Tag
Academia (2201)
Academic (1)
Accelerated approval (11)
Adcomms (20)
Allergies (92)
Alliances (45165)
ALS (109)
Alzheimer's disease (1291)
Antibody-drug conjugate (ADC) (129)
Approvals (14106)
Artificial intelligence (345)
Autoimmune disease (32)
Automation (21)
Bankruptcy (268)
Best Places to Work (9936)
BIOSECURE Act (14)
Biosimilars (106)
Biotechnology (60)
Bladder cancer (92)
Brain cancer (32)
Breast cancer (351)
Cancer (2778)
Cardiovascular disease (239)
Career advice (1858)
Career pathing (28)
CAR-T (172)
CDC (49)
Cell therapy (481)
Cervical cancer (22)
Clinical research (50941)
Collaboration (1079)
Company closure (4)
Compensation (411)
Complete response letters (23)
COVID-19 (2732)
CRISPR (61)
C-suite (398)
Cystic fibrosis (93)
Data (3088)
Decentralized trials (2)
Denatured (30)
Depression (74)
Diabetes (328)
Diagnostics (6651)
Digital health (20)
Diversity (5)
Diversity, equity & inclusion (43)
Drug discovery (147)
Drug pricing (123)
Drug shortages (27)
Duchenne muscular dystrophy (143)
Earnings (75361)
Editorial (49)
Employer branding (20)
Employer resources (134)
Events (87631)
Executive appointments (768)
FDA (15842)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (1)
Frontotemporal dementia (10)
Funding (881)
Gene editing (116)
Generative AI (33)
Gene therapy (378)
GLP-1 (724)
Government (4138)
Grass and pollen (5)
Guidances (312)
Healthcare (15553)
HIV (40)
Huntington's disease (22)
IgA nephropathy (37)
Immunology and inflammation (160)
Immuno-oncology (11)
Indications (40)
Infectious disease (2933)
Inflammatory bowel disease (132)
Inflation Reduction Act (11)
Influenza (83)
Intellectual property (127)
Interviews (399)
IPO (13115)
IRA (44)
Job creations (3087)
Job search strategy (1549)
Kidney cancer (10)
Labor market (49)
Layoffs (450)
Leadership (26)
Legal (6746)
Liver cancer (65)
Longevity (10)
Lung cancer (390)
Lymphoma (198)
Machine learning (16)
Management (51)
Manufacturing (447)
MASH (96)
Medical device (10808)
Medtech (10823)
Mergers & acquisitions (16362)
Metabolic disorders (789)
Multiple sclerosis (95)
NASH (15)
Neurodegenerative disease (132)
Neuropsychiatric disorders (32)
Neuroscience (1966)
NextGen: Class of 2025 (5269)
Non-profit (3810)
Now hiring (28)
Obesity (369)
Opinion (260)
Ovarian cancer (99)
Pain (107)
Pancreatic cancer (113)
Parkinson's disease (159)
Partnered (20)
Patents (291)
Patient recruitment (184)
Peanut (44)
People (48422)
Pharmaceutical (20)
Pharmacy benefit managers (15)
Phase I (15643)
Phase II (21947)
Phase III (17685)
Pipeline (2221)
Policy (226)
Postmarket research (2181)
Preclinical (6681)
Press Release (70)
Prostate cancer (164)
Psychedelics (33)
Radiopharmaceuticals (243)
Rare diseases (447)
Real estate (4878)
Recruiting (58)
Regulatory (18936)
Reports (37)
Research institute (2019)
Resumes & cover letters (337)
Rett syndrome (11)
RNA editing (11)
RSV (64)
Schizophrenia (98)
Series A (145)
Series B (106)
Service/supplier (6)
Sickle cell disease (59)
Special edition (20)
Spinal muscular atrophy (122)
Sponsored (35)
Startups (2898)
State (1)
Stomach cancer (12)
Supply chain (66)
Tariffs (64)
The Weekly (78)
Vaccines (1004)
Venture capital (48)
Weight loss (241)
Women's health (40)
Worklife (17)
Date
Today (118)
Last 7 days (368)
Last 30 days (1803)
Last 365 days (25704)
2025 (18215)
2024 (28635)
2023 (32567)
2022 (42848)
2021 (46331)
2020 (45275)
2019 (38438)
2018 (28967)
2017 (27347)
2016 (26755)
2015 (31393)
2014 (25870)
2013 (22256)
2012 (22969)
2011 (23242)
2010 (21835)
Location
Africa (844)
Alabama (66)
Alaska (6)
Arizona (191)
Arkansas (9)
Asia (33306)
Australia (5784)
California (6698)
Canada (2149)
China (582)
Colorado (309)
Connecticut (332)
Delaware (179)
Europe (79269)
Florida (1052)
Georgia (242)
Idaho (43)
Illinois (534)
India (38)
Indiana (335)
Iowa (15)
Japan (238)
Kansas (94)
Kentucky (28)
Louisiana (11)
Maine (72)
Maryland (949)
Massachusetts (4942)
Michigan (262)
Minnesota (375)
Mississippi (3)
Missouri (80)
Montana (26)
Nebraska (21)
Nevada (86)
New Hampshire (57)
New Jersey (2023)
New Mexico (28)
New York (1878)
North Carolina (1011)
North Dakota (9)
Northern California (3051)
Ohio (218)
Oklahoma (17)
Oregon (26)
Pennsylvania (1391)
Puerto Rico (4)
Rhode Island (33)
South America (1059)
South Carolina (33)
Southern California (2590)
Tennessee (114)
Texas (1069)
United States (25126)
Utah (227)
Virginia (178)
Washington D.C. (66)
Washington State (555)
West Virginia (4)
Wisconsin (73)
583,029 Results for "chiron corporation now novartis vaccines and diagnostics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Legal
BioNTech Attacked CureVac’s ‘Failed’ COVID Vaccine Program. The Rivals Are Now Merging
BioNTech said in 2022 that it faced “threats of a groundless patent infringement suit” from a company that was “unable to bring to market any product to help in the fight against COVID-19.” Now, the mRNA biotech is buying that very company.
June 18, 2025
·
4 min read
·
Nick Paul Taylor
Press Releases
Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older
August 18, 2025
·
6 min read
Press Releases
FLUMIST (Influenza, Vaccine Live, Intranasal), the nation’s only nasal spray flu vaccine, now available for home delivery
August 18, 2025
·
10 min read
Neuroscience
Novartis, BioArctic Partner To Penetrate the Blood-Brain Barrier
Novartis has bet up to $772 million to gain access to BioArctic’s BrainTransporter platform, which was leveraged in a partnership with Eisai to produce Leqembi.
August 27, 2025
·
1 min read
·
Tristan Manalac
Cardiovascular disease
Novartis Doubles Down on Argo Pact With Fresh $5.2B Commitment
Novartis and Argo Biopharma go back to January 2024, when the pharma first bet up to $4.165 billion across two RNAi agreements targeting cardiovascular diseases.
September 3, 2025
·
2 min read
·
Tristan Manalac
Mergers & Acquisitions
Novartis’ Busy BD Team Keeps 2025 Bolt-On Deal Promises
Executives at Novartis have not been shy about a desire to buy more companies, with cardiovascular a big focus. In total, the Swiss pharma has put $17.23 billion on the line in M&A and licensing deals this year.
September 9, 2025
·
2 min read
·
Annalee Armstrong
Mergers & acquisitions
Novartis Deals in Cardio Again, Dropping $1.4B To Acquire Tourmaline
Novartis has been investing heavily in its cardiovascular pipeline this year, forging partnerships with Flagship startup ProFound Therapeutics and China’s Argo Biopharmaceutical, among others.
September 9, 2025
·
2 min read
·
Tristan Manalac
Vaccines
After Moderna Pulled Its Shot, Combination Flu/COVID Vaccines Hang in Limbo
Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based combination shot that targets both influenza and COVID-19. Now, the entire vaccine sector is sizing up a new regulatory world, companies’ next steps uncertain.
July 21, 2025
·
7 min read
·
Dan Samorodnitsky
Deals
Arrowhead Nabs up to $2B Novartis Commitment for siRNA Parkinson’s Program
Novartis is licensing ARO-SNCA, a preclinical siRNA therapy for synucleinopathies, a group of neurodegenerative disorders including Parkinson’s disease.
September 2, 2025
·
1 min read
·
Annalee Armstrong
Press Releases
ProNephro AKI™ (NGAL), early detection test for Acute Kidney Injury, now commercially available to US Labs through BioPorto’s collaboration with Roche Diagnostics.
August 28, 2025
·
6 min read
1 of 58,303
Next
